Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
Roche Holding AG announced today that it has asked EU health authorities to re-examine data related to approving the pancreatic cancer treatment Tarceva.// The European Committee for Medicinal Products for Human Use (CHMP) had recently rejected the Tarceva
"People with pancreatic...
Drug Tarceva for End-stage Lung cancer
Patients with end-stage lung cancer who were given Tarceva
lived longer than patients// given a placebo.
Lung cancer is the most common cancer occurring both in men and women. Two studies were conducted by Canadian –led international research team with recruits from all over the world.
Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
...2018, however, Eli Lilly's share will drop below 16 percent as a result of generic erosion of Alimta and Gemzar, while increased uptake of Avastin and tarceva
will enable Roche to retain 29 percent of overall market share. Additionally, owing to the uptake of figitumumab, Pfizer will hold 23 percent of the o...
Drug Trials Show Modest Gains Against Lung Cancer
...were feeling better," he added. "That's a small step. Do we want more? Absolutely."
Yet a third trial found that combining the targeted therapies tarceva
(erlotinib) with Avastin (bevacizumab) as maintenance therapy in patients with advanced non-small cell lung cancer helped patients live longer before ...
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
... collaborate with Roche, Bayer and Onyx to explore tarceva
in hepatocellular carcinoma, a new disease area wh...successful, has the potential to expand the use of tarceva
beyond its current indications in second/third-lin...y will examine whether Nexavar in combination with tarceva
prolongs survival as compared to Nexavar alone. T...
Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
...urrent targeted therapies such as AstraZeneca's Iressa (gefitinib), Roche's tarceva
(erlotinib) and Jiangsu Simcere's Endostar (endostatin) and the launch of n...2006 report," added Ms. Wu. "In 2008, the increased prescription of Iressa, tarceva
and Endostar was the major factor contributing to this market growth."
Prescription Drug Benefits for Medicare Patients with Cancer to Cost More in 2009
...eevec had the largest increase in the
number of PDPs requiring prior authorization, with 70 percent of plans
requiring it, up from 35 percent in 2006. tarceva
had the next highest
increase, with 62 percent of plans requiring prior authorization in 2009, up
from 35 percent in 2006. Thalomid was next, with 68 ...
EGFR-targeting antibody licensed to Abbott
...ressed (over-produced) in cancer. Overexpression of EGFR occurs in more than 50% of some types of cancers. Current therapies that target EGFR, such as tarceva
and Erbitux, cause side-effects by targeting EGFR both when it is overexpressed on cancer cells and when it is present in usual amounts on normal cell...
Tests Could Predict Benefit From Cancer Drugs
...non-small cell lung cancer had a mutated form of the EGFR gene, the patients had a more aggressive cancer, with less time to live -- even after taking tarceva
(erlotinib), another targeted therapy that blocks EGFR.
It could be that more aggressive tumors lead to more mutant DNA in the blood, according to...
Determining genetic signature of lung tumors can help guide treatment
...rketed in the U.S., the trial reported in this article was supported by AstraZeneca, the drugs manufacturer. Several other EGFR inhibitors, including tarceva
(erlotinib), are either on the market or in clinical trials.
Tarceva in Medical Technology
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study
Published in the Journal of Clinical Oncology Showed Survival
Improvement in Patients with Pancreatic Cancer
MELVILLE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - OSI
Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results
published yesterday in the Journal of Clinical Oncology show that
adding Tarceva(R) (erlotinib) to gemcitabine chemotherapy
significantly improves survival when administered as firs...
University of California Los Angeles Selects Velos eResearch
... a once-a-day pill that targets a common form of adult leukemia called chronic myelogenous leukemia, or CML; Sprycel , also a pill that targets CML; tarceva
, a targeted lung cancer drug; and Avastin , a targeted drug for colorectal cancer, lung cancer and breast cancer.
With a membership of more...
Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R)
...irm Previously Demonstrated Survival Advantages of tarceva
in This Difficult-to-Treat Dise...- Adding Avastin (bevacizumab)
to a combination of tarceva
(erlotinib) and chemotherapy significantly
already established survival benefits of tarceva
in pancreatic cancer(4).
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor
Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
... in a mouse
xenograft model by complete dephosphorylation of PKB/Akt
MP470, SuperGen's multi-targeted tyrosine kinase inhibitor, in
combination with tarceva
was more effective than either treatment
alone in the inhibition of cell proliferation and phosphorylation
of Akt in EGF and PDGF pathways. Moreover, ...
Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment
Genmab scientists also used the model to test the effects of
tyrosine kinase inhibitors (TKI) such as the marketed products
Iressa and tarceva
on EGFr-expressing tumor cells. Tumor cells
expressing various mutated EGFr varied strongly in their
sensitivity to TKI therapy, whereas no difference...
Skin Rash Actually Signifies Better Outcomes for Pancreatic and
Lung Cancer Patients
Research, reports that for patients taking tarceva
who developed a
moderate to severe rash, survival ...out of the large Phase III
clinical trials testing tarceva
in advanced non-small cell lung
cancer and pancrea...he rash, Wacker said he fears
those who are taking tarceva
outside of a clinical trial may be
likely to stop ...
Tarceva in Biological News
Combination therapy shows promising results in patients with advanced lung cancer
...r Center reported.
Pairing the targeted therapy tarceva
with the anti-inflammatory drug Celebrex increased...factor receptor. Researchers theorized that giving tarceva
with Celebrex, a COX-2 inhibitor, would help battl...nal therapies, took several Celebrex pills and one tarceva
pill each day. After eight weeks, researchers look...
UCLA discovery will aid in treatment of patients with a deadly brain cancer
...ified in glioblastoma, making it a prime focus for therapies. Drugs such as tarceva
and Iressa target EGFR, blocking the cell signals that drive amplification ...ein and speed cancer growth. A subset of glioblastoma patients responded to tarceva
and Iressa, but it was not clear what characteristics made them respond to ...
Two designer drugs hit same lung cancer target, but only one is effective
...se with EGFR mutations will benefit from Iressa or tarceva
(erlotinib), while another group, without EGFR mut...ents tend to have a better outlook, and Iressa and tarceva
are particularly effective for them.
Mukohara a...he mutant EGFR receptor, you would pull Iressa and tarceva
off the shelf, not Erbitux."
Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol
...ped a way to test whether the new targeted therapy tarceva
and the widely used chemotherapy drug Taxol are ef... is working."
ABSTRACT # 1670
Sensitivity to tarceva
Depends on CDK2
In the first study, M. D. Ander... human breast cancer cell lines to varied doses of tarceva
and then measured activity of the CDK enzymes. The...
Tarceva in Biological Technology
China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits
...NSCLC"). The Company expects to offer the kits to its hospital
customers through its direct sales force in January 2009.
Currently, Iressa and tarceva
are commonly used drugs for the treatment of
patients with NSCLC. These drugs target the EGFR gene located at 7p12.
According to publications in medic...
Drug innovation beats marketing, patents and mergers
... owns in Genentech).
Genentech's pipeline is chock full of other new indications for its two lead cancer drugs as well as other cancer drugs called tarceva
and Rituxan. Additional cancer drugs (such as Omnitarq in Phase II as well as another drug in Phase I) provide the company with one of the best cancer...